Vaxcyte Q3 2026 net loss widens 40% to $297.1 million
PCVX•Vaxcyte’s third-quarter net loss widened 40% year over year to $297.1 million, while research and development expenses rose 29% to $270.3 million. VAX-31 met all prespecified primary endpoints in the OPUS-1 adult trial, and the company had $2.26 billion in cash, cash equivalents and investments at September 30, excluding about $1.1 billion raised through October offerings.
1. Quarterly results
Vaxcyte reported a third-quarter 2026 net loss of $297.1 million, 40% wider than a year earlier. Research and development expenses increased 29% to $270.3 million, primarily due to higher PCV development and manufacturing costs.
2. Trial and cash position
VAX-31 met all prespecified primary endpoints in the pivotal OPUS-1 adult trial, with a safety profile similar to PCV20 and PCV21. Vaxcyte said results from OPUS-2 and OPUS-3 are expected in the first half of 2027, supporting a planned biologics license application in early 2028. Cash, cash equivalents and investments totaled $2.26 billion at September 30, excluding approximately $1.1 billion raised through October offerings.
